Modified Oligonucleotides for Targeted APP Expression Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatments for neurodegenerative diseases such as Alzheimer's Disease, Alzheimer's Disease in Down Syndrome patients, and Cerebral Amyloid Angiopathy, characterized by the abnormal accumulation of β-amyloid plaques, which are associated with cognitive impairment and other symptoms.
Innovation Solution
Development of compounds and pharmaceutical compositions that reduce the amount or activity of APP RNA and protein, using modified oligonucleotides to target and hybridize with APP nucleic acid, thereby reducing the expression of APP and ameliorating symptoms of neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If modified oligonucleotides are used to target and hybridize with APP nucleic acid, then APP RNA and protein levels are reduced, but the complexity of the treatment increases
Solution Approach 1:
The patent employs modified oligonucleotides as intermediary molecules that hybridize with APP nucleic acid to reduce APP expression. These oligonucleotide intermediaries bind specifically to target mRNA sequences, preventing translation and reducing protein levels without requiring direct manipulation of the APP gene itself, thus simplifying the therapeutic approach while achieving effective reduction of APP RNA and protein.
2Object-generated harmful factors
If compounds are administered to reduce APP expression, then amyloid deposits are reduced, but the need for precise dosing and delivery increases complexity
Solution Approach 1:
The patent utilizes modified oligonucleotides with altered chemical parameters including modified sugar moieties and internucleoside linkages. These parameter changes enhance the stability, specificity, and cellular uptake of the therapeutic compounds, allowing for effective APP reduction with optimized dosing regimens that balance efficacy with ease of administration.
3Manufacturing precision
If modified oligonucleotides with modified sugar moieties are used, then hybridization specificity increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies modifications locally at specific positions within the oligonucleotide sequence rather than uniformly across all nucleotides. Modified sugar moieties and internucleoside linkages are strategically placed at key positions to maximize hybridization specificity and stability while minimizing the overall complexity of synthesis and manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively decrease APP RNA and protein levels, leading to improvements in cognitive impairment, behavioral symptoms, and amyloid deposits, providing therapeutic benefits for neurodegenerative conditions.
Implementation Method 1
compounds useful for reducing expression of APP RNA are oligomeric compounds... compounds useful for reducing expression of APP RNA are modified oligonucleotides... oligonucleotides that are complementary to a target nucleic acid
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA in a cell or animal, and in certain instances reducing the amount of APP protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease or disorder. Such symptoms and hallmarks include cognitive impairment, including a decline in memory and language skills, behavioral and psychological symptoms such as apathy and lack of motivation, gait disturbances and seizures, progressive dementia, and abnormal amyloid deposits.